相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells
Mi-Jung Kim et al.
CANCER LETTERS (2013)
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
Priya Koppikar et al.
NATURE (2012)
STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma
Anna Scuto et al.
CANCER RESEARCH (2011)
Signal transducer and activator of transcription 3 inhibitors: a patent review
Brent D. G. Page et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2011)
PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML
S. Kurahashi et al.
ONCOGENE (2011)
FLT3 as a therapeutic target in AML: still challenging after all these years
Thomas Kindler et al.
BLOOD (2010)
Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and re-establishes transformed Philadelphia chromosome-positive leukemia in NOD/SCID/IL-2R gamma c(-/-) mice
Ryohei Tanizaki et al.
CANCER SCIENCE (2010)
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches
Stephen Y. Lai et al.
DRUG RESISTANCE UPDATES (2010)
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML
Jianbiao Zhou et al.
BLOOD (2009)
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation
Yukimasa Shiotsu et al.
BLOOD (2009)
Targeting STAT3 in cancer: how successful are we?
Pedbin Yue et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance
Nadine N. Bewry et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD
M. Okamoto et al.
LEUKEMIA (2007)
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation
XH Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
JAK-STAT signaling activated by Abl oncogenes
NN Danial et al.
ONCOGENE (2000)
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
F Hayakawa et al.
ONCOGENE (2000)
分享论文
